Searched for
COPD DRUGS
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...- Quadria, PE funds eye stake in Samarth Lifesciences; deal may value firm at Rs 4,500 croreQuadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction a...
- Chuck Negron, founding member of ‘Three Dog Night’ who was once engaged in drugs, dies at 83, cause of death revealed; details insideChuck Negron, a founding member of Three Dog Night, has died. Known for his lead vocals on hits like "Joy to the World," Negron's career wa...
- Respiratory drug sales peak in November amid worsening AQIIndia's air quality decline is boosting medicines for breathing problems. The respiratory drug market grew 8% last month, a rise from previ...
- Glenmark launches fixed-dose triple therapy for COPDGlenmark Pharmaceuticals has launched a groundbreaking nebulised triple therapy for COPD. This single, easy-to-use treatment combines three...
- AstraZeneca's asthma drug fails 'smoker's lung' studyAstraZeneca's Fasenra failed to reduce flare-ups in COPD patients in a late-stage trial, a setback for the company's efforts to address the...
- Verona Pharma stock jumps 20% on $10B Merck deal—can FDA-approved Ohtuvayre reshape COPD care?Verona Pharma stock jumped 20% after Merck announced it will acquire the British biotech in a $10 billion deal. Merck will pay $107 per sha...
- EU approves Sanofi's Dupixent for 'smoker's lungs'Sanofi and Regeneron received EU approval for broader use of Dupixent in treating chronic obstructive pulmonary disease (COPD), a significa...
- Lupin unit introduces inhaler for asthma patients in GermanyDrug firm Lupin on Friday said its unit has launched a pressurized metered dose inhaler for the treatment of asthma and chronic obstructive...
- GSK launches once daily, single inhaler-triple therapy for COPD patientsTrelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is...
- Zydus Pharmaceuticals (USA) Inc gets final US FDA approval to market Roflumilast tabletsRoflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chro...
- Cipla scales up offerings, investments as it eyes global lung specialty leadershipDrugmaker Cipla said it is scaling up offerings and expanding access to medicines, inhaler devices, diagnostics, as it aspires to become th...
- Cipla gets USFDA nod for inhalation productThe company has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mc...
- Glenmark Pharma launches COPD treatment inhaler in UKDrug firm Glenmark Pharma on Tuesday announced the launch of Tiotropium Bromide Dry Powder Inhaler, used in the treatment of chronic obstru...
- Zydus Cadila launches new product for COPD patients in IndiaDrug firm Zydus Cadila on Thursday said it is launching pressurized metered dose inhaler for patients suffering from Chronic Obstructive Pu...
- AstraZeneca gets marketing nod for asthma drug SymbicortResults from AstraZeneca's two clinical studies have shown that the addition of formoterol to budesonide improved asthma symptoms and lung ...
- Cipla asks government to revoke five patents held by NovartisCipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...
- Glenmark takes 17% knock, biggest in 2 monthsGlenmark, one of the top 10 pharma companies in India by market capitalisation, witnessed a sharp fall of 17% in its intra-day stock price ...
- Glenmark gets US nod for drug trialsEnding a long wait for Glenmark Pharmaceuticals, the US Food and Drug Administration (FDA) finally gave its nod to the Indian drugmaker to ...
- Ranbaxy-GSK to develop respiratory drugRanbaxy will develop a respiratory inflammation drug in collaboration GlaxoSmithKline (GSK), as part of their new multi-year R&D agreement.
Load More
